This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swift, L. P. Articles by Cutts, S. M. Search for Related Content PubMed PubMed Citation Articles by Swift, L. P. Articles by Cutts, S. M.

Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death

¹ Department of Biochemistry, La Trobe University, Victoria, Australia; ² Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Petach Tikva, Israel; and ³ Chemistry Department, Bar Ilan University, Ramat Gan, Israel

Requests for reprints: Don R. Phillips, Department of Biochemistry, La Trobe University, Victoria, 3086, Australia. Phone: 61-3-94792182; Fax: 61-3-94792467; E-mail: d.phillips{at}latrobe.edu.au.

Doxorubicin (Adriamycin) is one of the most commonly used chemotherapeutic drugs and exhibits a wide spectrum of activity against solid tumors, lymphomas, and leukemias. Doxorubicin is classified as a topoisomerase II poison, although other mechanisms of action have been characterized. Here, we show that doxorubicin-DNA adducts (formed by the coadministration of doxorubicin with non-toxic doses of formaldehyde-releasing prodrugs) induce a more cytotoxic response in HL-60 cells than doxorubicin as a single agent. Doxorubicin-DNA adducts seem to be independent of classic topoisomerase II–mediated cellular responses (as observed by employing topoisomerase II catalytic inhibitors and HL-60/MX2 cells). Apoptosis induced by doxorubicin-DNA adducts initiates a caspase cascade that can be blocked by overexpressed Bcl-2, suggesting that adducts induce a classic mode of apoptosis. A reduction in the level of topoisomerase II–mediated double-strand-breaks was also observed with increasing levels of doxorubicin-DNA adducts and increased levels of apoptosis, further confirming that adducts exhibit a separate mechanism of action compared with the classic topoisomerase II poison mode of cell death by doxorubicin alone. Collectively, these results indicate that the presence of formaldehyde transfers doxorubicin from topoisomerase II–mediated cellular damage to the formation of doxorubicin-DNA adducts, and that these adducts are more cytotoxic than topoisomerase II–mediated lesions. These results also show that doxorubicin can induce apoptosis by a non-topoisomerase II–dependent mechanism, and this provides exciting new prospects for enhancing the clinical use of this agent and for the development of new derivatives and new tumor-targeted therapies. (Cancer Res 2006; 66(9): 4863-71)

This article has been cited by other articles:

				R. Sullivan and C. H. Graham Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1 Mol. Cancer Ther., June 1, 2009; 8(6): 1702 - 1713. [Abstract] [Full Text] [PDF]

				K. E. Coldwell, S. M. Cutts, T. J. Ognibene, P. T. Henderson, and D. R. Phillips Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations Nucleic Acids Res., September 1, 2008; 36(16): e100 - e100. [Abstract] [Full Text] [PDF]

				B. J. Evison, F. Chiu, G. Pezzoni, D. R. Phillips, and S. M. Cutts Formaldehyde-Activated Pixantrone Is a Monofunctional DNA Alkylator That Binds Selectively to CpG and CpA Doublets Mol. Pharmacol., July 1, 2008; 74(1): 184 - 194. [Abstract] [Full Text] [PDF]

				X.-J. Wang, Z. Sun, N. F. Villeneuve, S. Zhang, F. Zhao, Y. Li, W. Chen, X. Yi, W. Zheng, G. T. Wondrak, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis, June 1, 2008; 29(6): 1235 - 1243. [Abstract] [Full Text] [PDF]

				V. Stierle, M. Duca, L. Halby, C. Senamaud-Beaufort, M. L. Capobianco, A. Laigle, B. Jolles, and P. B. Arimondo Targeting MDR1 Gene: Synthesis and Cellular Study of Modified Daunomycin-Triplex-Forming Oligonucleotide Conjugates Able to Inhibit Gene Expression in Resistant Cell Lines Mol. Pharmacol., May 1, 2008; 73(5): 1568 - 1577. [Abstract] [Full Text] [PDF]

				B. J. Evison, O. C. Mansour, E. Menta, D. R. Phillips, and S. M. Cutts Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent Nucleic Acids Res., June 28, 2007; 35(11): 3581 - 3589. [Abstract] [Full Text] [PDF]

				S. M. Cutts, L. P. Swift, V. Pillay, R. A. Forrest, A. Nudelman, A. Rephaeli, and D. R. Phillips Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate Mol. Cancer Ther., April 1, 2007; 6(4): 1450 - 1459. [Abstract] [Full Text] [PDF]

				H. Zhu, M. Huang, F. Yang, Y. Chen, Z.-H. Miao, X.-H. Qian, Y.-F. Xu, Y.-X. Qin, H.-B. Luo, X. Shen, et al. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II Mol. Cancer Ther., February 1, 2007; 6(2): 484 - 495. [Abstract] [Full Text] [PDF]